[go: up one dir, main page]

WO2004050621A3 - Indol derivatives and their use as kinase inhibitors - Google Patents

Indol derivatives and their use as kinase inhibitors Download PDF

Info

Publication number
WO2004050621A3
WO2004050621A3 PCT/US2003/036988 US0336988W WO2004050621A3 WO 2004050621 A3 WO2004050621 A3 WO 2004050621A3 US 0336988 W US0336988 W US 0336988W WO 2004050621 A3 WO2004050621 A3 WO 2004050621A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitors
indol derivatives
indol
derivatives
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036988
Other languages
French (fr)
Other versions
WO2004050621A2 (en
Inventor
Steven W Andrews
Michael E Garst
Xialing Guo
Jonathan J Hebert
Thomas Malone
Julie A Wurster
Iii Clarence Eugene Hull
Yuan-Xing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,097 external-priority patent/US6699863B1/en
Priority claimed from US10/389,416 external-priority patent/US6747025B1/en
Priority to AU2003295658A priority Critical patent/AU2003295658A1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to DE10393799T priority patent/DE10393799T5/en
Priority to CA002507780A priority patent/CA2507780A1/en
Priority to BR0316744-5A priority patent/BR0316744A/en
Priority to JP2004570761A priority patent/JP4879492B2/en
Priority to GB0511267A priority patent/GB2410744B/en
Publication of WO2004050621A2 publication Critical patent/WO2004050621A2/en
Publication of WO2004050621A3 publication Critical patent/WO2004050621A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
PCT/US2003/036988 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors Ceased WO2004050621A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB0511267A GB2410744B (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease
JP2004570761A JP4879492B2 (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of diseases
AU2003295658A AU2003295658A1 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors
DE10393799T DE10393799T5 (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of diseases
CA002507780A CA2507780A1 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors
BR0316744-5A BR0316744A (en) 2002-11-27 2003-11-19 Kinase Inhibitors for Disease Treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30697502A 2002-11-27 2002-11-27
US10/306,975 2002-11-27
US10/307,097 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/389,416 2003-03-13
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease

Publications (2)

Publication Number Publication Date
WO2004050621A2 WO2004050621A2 (en) 2004-06-17
WO2004050621A3 true WO2004050621A3 (en) 2004-07-15

Family

ID=32475339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036988 Ceased WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Country Status (7)

Country Link
AU (1) AU2003295658A1 (en)
BR (1) BR0316744A (en)
CA (1) CA2507780A1 (en)
DE (1) DE10393799T5 (en)
ES (1) ES2292329B2 (en)
GB (1) GB2410744B (en)
WO (1) WO2004050621A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114371A1 (en) * 2005-04-28 2006-11-02 Boehringer Ingelheim International Gmbh Novel compounds for treating inflammatory diseases
WO2007087419A2 (en) * 2006-01-24 2007-08-02 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CN104211632B (en) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2 indolone derivatives with tyrosine-kinase enzyme inhibition activity and preparation method and application
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2003015608A2 (en) * 2001-08-15 2003-02-27 Sugen, Inc. Combination therapy for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 18, no. 3, June 2003 (2003-06-01), pages 243 - 252, XP008030892 *

Also Published As

Publication number Publication date
ES2292329B2 (en) 2009-09-16
AU2003295658A1 (en) 2004-06-23
CA2507780A1 (en) 2004-06-17
GB2410744B (en) 2006-04-12
BR0316744A (en) 2005-10-18
GB0511267D0 (en) 2005-07-13
ES2292329A1 (en) 2008-03-01
GB2410744A (en) 2005-08-10
DE10393799T5 (en) 2005-10-13
WO2004050621A2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
MX9606401A (en) Indolinone compounds for the treatment of disease.
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
DE602004006433D1 (en) PYRROL SUBSTITUTED INDOLE AS INHIBITORS OF PAI-1
TNSN03055A1 (en) 3-(4-amidopyrrol -2-ylmethlidene)-2- indolinone derivatives as protein kinase inhibitors
AU2003302626A1 (en) 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
AU9158498A (en) Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
YU61402A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
NO20054359L (en) Cyclic protein tyrosine kinase inhibitors
WO1999057117A3 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
EP1534695A4 (en) INHIBITORS OF TYROSINE KINASES
WO2006076442A3 (en) Triazolopyrimidine derivatives
AU2003233455A1 (en) Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
NO20043842L (en) New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX
WO2007087419A3 (en) Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
WO2004050621A3 (en) Indol derivatives and their use as kinase inhibitors
EA200801430A1 (en) TRIAZOLE DERIVATIVES
BRPI0416994A (en) Advanced indolinone-based protein kinase inhibitors
WO2007008985A3 (en) Kinase inhibitors
WO2006050333A3 (en) Methods and compositions for modulating apoptosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2507780

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 200550033

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200550033

Country of ref document: ES

Ref document number: 2004570761

Country of ref document: JP

Ref document number: 2003295658

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 0511267

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20031119

ENP Entry into the national phase

Ref document number: PI0316744

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 200550033

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200550033

Country of ref document: ES

Kind code of ref document: A